According to GSK and Innoviva, the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol DPI has been approved in Canada for the treatment of COPD in patients for whom treatment with an ICS/LABA combination is inadequate. Trelegy Ellipta should be available in Canada sometime in June of this year, the companies said.
Trelegy Ellipta was approved in the US in September 2017 and received European approval in November 2017.
GSK VP Country Medical Director Susie Barnes commented, “COPD is a progressive and debilitating lung disease that can worsen over time, and represents a significant burden to patients and healthcare systems. The addition of Trelegy Ellipta to our portfolio of respiratory medicines is an important milestone for GSK, building on our long heritage in this area and our relentless drive to ensure the right treatment for the right patient.”
Innoviva Senior VP and Chief Scientific Officer Theodore J. Witek Jr. said, “We are delighted that the long-standing collaboration between Innoviva and GSK to develop respiratory medicines that meet patient needs has led to the approval of Trelegy Ellipta in Canada. This is a significant milestone as healthcare professionals now have a single inhaler triple therapy option to consider for their patients with COPD.”
Read the GSK and Innoviva press release.
